J Med Virol. 2018 Dec 5. doi: 10.1002/jmv.25373. [Epub ahead of print]
VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
Ben S1,2, Yan WJ1, Xia W1, Juan FJ1, Li L1, Cheng PX1, Jun LJ3, Tuan TX4.
Author information
1
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
2
The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
3
The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
4
The Affiliated Pizhou Hospital of Xuzhou Medical University, Xuzhou, China.
Abstract
AIM:
To evaluate the predictive value of vitamin D and its metabolic pathway gene polymorphisms in response to pegylated interferon (Peg-IFN) in HBeAg-positive CHB patients.
METHODS:
119 HBeAg-positive CHB patients who received Peg-IFN monotherapy for 48 weeks and then were followed-up for another 48 weeks were prospectively enrolled; baseline 25-(OH)D and HBV serologic marker levels were detected, 9 critical single nucleotide polymorphisms within vitamin D metabolism were genotyped.
RESULTS:
45 (37.8%), 44 (37.0%), 35 (29.4%) and 11 (9.2%) of the patients achieved VR, HBeAg loss, CR and HBsAg level <200 IU/ml at the end of treatment (EOT; week 48), respectively; 42 (35.3%) and 6 (5.0%) people achieved HBeAg and HBsAg loss at the end of follow-up (EOF; week 96). Baseline HBeAg level was independent predictor of VR (OR=0.470, 95% CI: 0.294-0.751, P=0.002), HBeAg loss (OR=0.395, 95% CI: 0.243-0.643, P<0.001), CR (OR=0.392, 95% CI: 0.215-0.714, P=0.002) at EOT and HBeAg loss at EOF (OR=0.334, 95% CI: 0.203-0.559, P<0.001); baseline HBsAg level itself was independent predictor of both HBsAg<200 IU/ml at EOT (OR=0.257, 95% CI: 0.103-0.642, P=0.004) and HBsAg loss at EOF (OR=0.232, 95% CI: 0.077-0.702, P=0.010). Age was also independent predictors of HBsAg loss at EOF (OR=0.775, 95% CI: 0.634-0.948, P=0.013). Concerning genetic variation of VDR rs7975232/ApaI, A allele was the genetic independent predictor of VR at EOT (OR=1.824, 95% CI: 1.024-3.248, P=0.041) and HBsAg loss at EOF (OR=3.566, 95% CI: 1.057-12.029, P=0.040).
CONCLUSIONS:
Genetic variation of VDR rs7975232/ApaI is a pretreatment predictor of sustained HBsAg loss in HBeAg-positive CHB patients with Peg-IFN monotherapy. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Chronic hepatitis B; Interferon; Polymorphism; Vitamin D
